Allergy Therapeutics PLC
LSE:AGY

Watchlist Manager
Allergy Therapeutics PLC Logo
Allergy Therapeutics PLC
LSE:AGY
Watchlist
Price: 6.25 GBX -0.79% Market Closed
Market Cap: 297.9m GBX
Have any thoughts about
Allergy Therapeutics PLC?
Write Note

Allergy Therapeutics PLC
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Allergy Therapeutics PLC
Additional Paid In Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
Allergy Therapeutics PLC
LSE:AGY
Additional Paid In Capital
ÂŁ154.7m
CAGR 3-Years
11%
CAGR 5-Years
7%
CAGR 10-Years
9%
GlaxoSmithKline PLC
LSE:GSK
Additional Paid In Capital
ÂŁ3.5B
CAGR 3-Years
2%
CAGR 5-Years
2%
CAGR 10-Years
3%
AstraZeneca PLC
LSE:AZN
Additional Paid In Capital
$35.2B
CAGR 3-Years
64%
CAGR 5-Years
35%
CAGR 10-Years
24%
Verona Pharma PLC
NASDAQ:VRNA
Additional Paid In Capital
$621.6m
CAGR 3-Years
18%
CAGR 5-Years
34%
CAGR 10-Years
N/A
Hikma Pharmaceuticals PLC
LSE:HIK
Additional Paid In Capital
$282m
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
0%
Dechra Pharmaceuticals PLC
LSE:DPH
Additional Paid In Capital
ÂŁ596m
CAGR 3-Years
13%
CAGR 5-Years
11%
CAGR 10-Years
17%
No Stocks Found

Allergy Therapeutics PLC
Glance View

Market Cap
297.9m GBX
Industry
Pharmaceuticals

Allergy Therapeutics Plc is a biotechnology company. The company is headquartered in Worthing, West Sussex and currently employs 601 full-time employees. The company went IPO on 2004-10-11. The firm is focused on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines. Its segments include Central Europe, which include segments, such as Germany, Austria, Switzerland and the Netherlands; Southern Europe, which includes Italy, Spain and Other; the United Kingdom, and Rest of World. The company sells both injectable and sublingual allergen-specific immunotherapies. Its pipeline candidates include Grass MATA MPL, Birch MATA MPL, Ragweed MATA MPL, Trees MATA MPL and Peanut SCIT. Its vaccine candidates outside allergy include disease areas, including cancer, asthma, atopic dermatitis and psoriasis. Its products include Pollinex, Pollinex Quattro, Oralvac, Acarovac Plus, Venomil, VLP Peanut and ImmunoBON.

AGY Intrinsic Value
4.33 GBX
Overvaluation 31%
Intrinsic Value
Price

See Also

What is Allergy Therapeutics PLC's Additional Paid In Capital?
Additional Paid In Capital
154.7m GBP

Based on the financial report for Dec 31, 2023, Allergy Therapeutics PLC's Additional Paid In Capital amounts to 154.7m GBP.

What is Allergy Therapeutics PLC's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 10Y
9%

Over the last year, the Additional Paid In Capital growth was 30%. The average annual Additional Paid In Capital growth rates for Allergy Therapeutics PLC have been 11% over the past three years , 7% over the past five years , and 9% over the past ten years .

Back to Top